## 32-6965: ErbB2 Human, Sf9

```
Alternative Name
:
Receptor tyrosine-protein kinase erbB-2, EC 2.7.10.1, p185erbB2, C-erbB-2, NEU proto-oncogene, Tyrosine kinase-type cell surface receptor HER2, MLN 19, CD340 antigen, NEU, NGL, HER2, TKR1, HER-2, c-erb B2, HER-2/neu.
```


## Description

Source: Sf9, Baculovirus cells.
Sterile Filtered clear solution.
HER-2/neu (erbB-2) encodes an 185-kDa orphan receptor tyrosine kinase that is constitutively active as a dimer and displays potent oncogenic activity when overexpressed. Herstatin, as the product of alternative HER-2 transcript, retains intron 8. The herstatin mRNA is expressed in normal human fetal kidney and liver, but is at reduced levels relative to p185HER-2 mRNA in carcinoma cells that contain an amplified HER-2 gene. Herstatin appears to be an inhibitor of p185HER-2, because it disrupts dimers, reduces tyrosine phosphorylation of p185, and inhibits the anchorage-independent growth of transformed cells that overexpress HER-2.
ErbB2 Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 638 amino acids (23-652) and having a molecular mass of 70.4 kDa (Molecular size on SDS-PAGE will appear at approximately $70-100 \mathrm{kDa}$ ). ErbB2 is fused to 8 amino acid $\operatorname{lgG}$ His-Tag at C-terminus and purified by proprietary chromatographic techniques.

## Product Info

## Amount :

Purification :
Content :

## Storage condition :

Amino Acid :
$1 \mu \mathrm{~g} / 5 \mu \mathrm{~g}$
Greater than $85.0 \%$ as determined by SDS-PAGE.
ErbB2 protein solution ( $0.25 \mathrm{mg} / \mathrm{ml}$ ) containing Phosphate Buffered Saline ( pH 7.4 ) and $10 \%$ glycerol.
Store at $4^{\circ} \mathrm{C}$ if entire vial will be used within $2-4$ weeks. Store, frozen at $-20^{\circ} \mathrm{C}$ for longer periods of time. For long term storage it is recommended to add a carrier protein ( $0.1 \%$ HSA or BSA).Avoid multiple freeze-thaw cycles.
TQVCTGTDMK LRLPASPETH LDMLRHLYQG CQVVQGNLEL TYLPTNASLS FLQDIQEVQG YVLIAHNQVR QVPLQRLRIV RGTQLFEDNY ALAVLDNGDP LNNTTPVTGA SPGGLRELQL RSLTEILKGG VLIQRNPQLC YQDTILWKDI FHKNNQLALT LIDTNRSRAC HPCSPMCKGS RCWGESSEDC QSLTRTVCAG GCARCKGPLP TDCCHEQCAA GCTGPKHSDC LACLHFNHSG ICELHCPALV TYNTDTFESM PNPEGRYTFG ASCVTACPYN YLSTDVGSCT LVCPLHNQEV TAEDGTQRCE KCSKPCARVC YGLGMEHLRE VRAVTSANIQ EFAGCKKIFG SLAFLPESFD GDPASNTAPL QPEQLQVFET LEEITGYLYI SAWPDSLPDL SVFQNLQVIR GRILHNGAYS LTLQGLGISW LGLRSLRELG SGLALIHHNT HLCFVHTVPW DQLFRNPHQA LLHTANRPED ECVGEGLACH QLCARGHCWG PGPTQCVNCS QFLRGQECVE ECRVLQGLPR EYVNARHCLP CHPECQPQNG SVTCFGPEAD QCVACAHYKD PPFCVARCPS GVKPDLSYMP IWKFPDEEGA CQPCPINCTH SCVDLDDKGC PAEQRASPLT LEHHHHHH.

